medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 5

<< Back Next >>

Med Int Mex 2021; 37 (5)

Impact of adherence to pharmacological treatment on quality of life in patients with heart failure

Rojano-Rada JA, Suárez-Marcano S

Language: Spanish
References: 16
Page: 665-673
PDF size: 231.82 Kb.


ABSTRACT

Objective: To assess the impact of adherence to pharmacological treatment on quality of life in patients with heart failure.
Materials and Methods: Single-center, descriptive, longitudinal study carried out in patients older than 18 years with a diagnosis of heart failure according to the Framingham criteria, who attended the outpatient clinic of the Internal Medicine service of the Central Hospital of the IVSS Dr. Miguel Pérez Carreño, June 2018 as of September 2019.
Results: One hundred and twenty patients were evaluated, being 55.8% female; 30% of the patients with high blood pressure were in grade I and 60% had suboptimal treatment for hear failure. NT-proBNP levels were performed at 100%, with positivity in 77.5%, and high values were found in 93 patients. Regarding LVEF, 41.6% of patients had ‹ 40%, 36.8% were › 50% and another group with 21.6% was between 40-49%, it is noteworthy that a 6.6% had recovered LVEF. The correlation between NT-proBNP and LVEF was not statistically significant (p = 0.290); however, patients with a higher value of NT-proBNP and a lower LVEF were associated with a worse prognosis.
Conclusions: It is evident that the patients more adherent to the treatment will have a better quality of life, which would have a lower risk of hospitalizations and an adequate prognosis of the disease.


REFERENCES

  1. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013; 6: 606-619. doi: 10.1161/ HHF.0b013e318291329a.

  2. Ponikowski P, Voors AA, Anker SD, Bueno H, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-2200. doi: 10.1093/ eurheartj/ehw128.

  3. World Health. Organization. The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403- 1409. doi: 10.1016/0277-9536(95)00112-k.

  4. Joseph S, Novak E, Arnold S, Jones P, Khattak H, Platts A, et al. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail 2013; 6 (6): 1139-46. doi: 10.1161/CIRCHEARTFAILURE. 113.000359.

  5. Hood S, Giazzon A, Seamon G, Lane K, Wang J, Eckert G. Association between medication adherence and the outcomes of heart failure. Pharmacotherapy 2018; 38 (5): 539-545. doi: 10.1002/phar.2107.

  6. Ruppar T, Cooper P, Mehr D, Delgado J, Dunbar-Jacob J. Medication adherence interventions improve heart failure mortality and readmission rates: Systematic review and meta-analysis of controlled trials. J Am Heart Assoc 2016; 5 (6). e002606. doi: 10.1161/JAHA.115.002606.

  7. Val-Jiménez A, Amorós-Ballestero G, Martínez P, Fernández ML, León M. Estudio descriptivo del cumplimiento del tratamiento farmacológico antihipertensivo y validación del test de Morisky y Green. Aten Primaria1992; 10: 767-70.

  8. Davis NJ, Billet HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 2005; 39: 632-6. doi: 10.1345/ aph.1E464.

  9. Ministerio del Poder Popular para la Salud, 2011. Anuario De Mortalidad. Caracas.

  10. Farré N, Vela E, Clèries M, Bustins M, Cainzos M, Enjuanes C, et al. Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients. PLoS One 2017; 12 (2): e0172745. doi: 10.1371/journal. pone.0172745.

  11. Valdivia-Marchal M, Zambrana-Luque JL, Girela-López E, Font-Ugalde P, et al. Factores predictores de mortalidad en pacientes hospitalizados por insuficiencia cardíaca. Anales del Sistema Sanitario de Navarra 2020; 43: 57-67. https:// dx.doi.org/10.23938/assn.0753.

  12. Castro P, Vukasovic J, Garcés E, Sepúlveda L, Ferrada M, Alvarado S. Insuficiencia cardíaca en hospitales chilenos: resultados del Registro Nacional de Insuficiencia Cardíaca, Grupo ICARO. Rev Méd Chile 2004; 132 (6): 655-662. http:// dx.doi.org/10.4067/S0034-98872004000600001.

  13. Jimeno A, Gil V, Merino J, García M, Jordán A, Guerrero L. Validez de los criterios clínicos de Framingham para el diagnóstico de insuficiencia cardíaca sistólica. Rev Clin Esp 2006; 206 (10): 495-8. DOI: 10.1016/S0014- 2565(06)72875-2.

  14. Muñoz O, Sierra E, Zapata A, Isaza M, Muñoz M, Sánchez J, Caracterización sociodemográfica y clínica de una población con falla cardíaca aguda: cohorte MED-ICA. Rev Colomb Cardiol 2018; 25 (3): 200-208. DOI: 10.1016/j. rccar.2017.12.021.

  15. Díez C, Lupón J, Ferrer M, Domingo M, Zamora E, Santesmases J. Insuficiencia cardiaca con fracción de eyección recuperada: ¿un nuevo tipo de IC a tenor del perfil clínico? Rev Esp Cardiol 2016; 69 Supl 1: 286.

  16. Spinar J, Spinarova L, Malek F, Ludka O, Krejci J, Ostadal P. Prognostic value of NT-proBNP added to clinical parameters to predict two-year prognosis of chronic heart failure patients with mid-range and reduced ejection fraction – A report from FAR NHL prospective registry. PLoS One 2019; 14 (3): e0214363. doi: 10.1371/journal.pone.0214363.




2020     |     www.medigraphic.com